← Stocks · IRLA record
Signal record & history · Trifecta Signals
IRulya has been flagged by the Trifecta screener 2 times since 2022. 1 signal confirmed; the median confirmed signal is down 97.1% since its Early Signal.
Price refreshes every trading day after the close.
Full interactive chart ↗ · partner link
Daily closes · through the most recent close
Price history from Jan 2018 · Signal tracking began Jan 2022
Headline statistics: confirmed signals only, measured from the confirmation price.
First signal Feb 2022 · Latest Feb 2026 · Confirmed 1 of 2 Early · Latest close in the chart data: Wed, Nov 4, 2026
Groups are mutually exclusive — every confirmed signal sits in exactly one.
Since February 2022, IRulya has had two Early signals, one confirmed. Its one decided signal gained +10% within 90 days, and it did not finish ahead of the S&P 500 since confirmation. One Early signal never confirmed and counts in no statistic.
Every Early signal in the record, newest first.
Members see every signal below, and the group mix above.
Membership unlocks the complete signal timeline for IRLA and every other stock in the record — group tags, caution flags, and the full screener.
Already a member? Sign in and this page unlocks.
IRulya Therapeutics sits in the Healthcare sector, in the Biotechnology industry. With a market value of about $356 million, the company falls in the small-cap group.
The strongest run on IRulya Therapeutics’ record followed a confirmation in February 2022, falling about 35% over the following 90 days. Classification adds texture: it sat in the small-cap group when that signal fired.
IRLA closed Wednesday, November 4 at $31.67, down 4.5% on the day. The last five sessions span about $32 to about $34.
